Share: Facebook Twitter LinkedIn
Activity Provided By:

Purdue University

Prostate Cancer: The future of PARP inhibitor combination and the evolving paradigm of treatment strategies

Access Activity

Overview / Abstract:

Target Audience

Oncologists, physician assistants, nurse practioners, pharmacists and other healthcare professionals involved in the treatment of prostate cancer.

Program Overview

The overall objective for this program is to improve both the knowledge and competence of healthcare professionals who manage patients with prostate cancer using PARP-inhibitor Combination Treatments.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Discuss the mechanism of action and biological basis of PARP inhibition.
Debate the clinical rationale for using PARP inhibitor combinations as treatments for prostate cancer.
Describe the clinical trial and research data to support the use of PARP inhibitors in combination with androgen receptor targeted therapies for prostate cancer in the clinical setting.
Discuss the potential and rationale for using PARP inhibitor combinations in metastatic castration resistant prostate cancer (mCRPC).
Evaluate how to best transfer research and clinical trial findings to the community hospital setting.

Expiration

Jul 29, 2023

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Dr. Neeraj Agarwal
Salt Lake City, Utah

Dr. Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.

Dr. Agarwal is an internationally recognized physician scientist in the field of genitourinary cancers. He is the overall study chair of multiple Phase I/II and Phase III trials, and serves as a steering committee member of numerous other trials. He has received SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. After receiving his medical training at the All India Institute of Medical Sciences in New Delhi, he completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa, followed by a hematology-oncology fellowship at HCI.

Dr. Agarwal has authored more than 350 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN guideline committees for bladder and kidney cancers. He is an advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, and leads early therapeutics in the SWOG genitourinary cancers committee. He holds numerous scientific communications leadership roles, including chief editor of the ASCO Daily News, specialty editor for ASCO’s cancer.net site, and editorial board member of several journals, including Journal of Clinical Oncology. He also serves as a member of the ASCO Genitourinary Cancers Advisory Panel. Recently, Dr. Agarwal was appointed as the Senior Director for Clinical Research Innovation, directly reporting to the cancer center director at the Huntsman Cancer Institute.

FACULTY_NAME
Dr. Neal Shore
Myrtle Beach, SC

Dr. Neal Shore graduated both Duke University and Duke University Medical School. He completed his general surgery/urology residence at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He is the Medical Director, for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 400 clinical trials, focusing mainly for GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare, US. He has more than 250 peer reviewed publications and numerous book chapters. He serves on the SITC Guidelines Committee for Bladder Cancer as well as the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. He is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and also serves as Editor, Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.

FACULTY_NAME
Dr. Alicia Morgans
Boston, MA

Alicia Morgans is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation and the Department of Defense. She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association, and is a member of the cardio-oncology committee of the American Heart Association. Since 2016, she has been President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research.

Sponsors / Supporters / Grant Providers

Pfizer, Inc.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Prostate Cancer Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map